Skip to main content
. 2019 Sep 29;75(9):1618–1623. doi: 10.1093/gerona/glz213

Table 3.

Associations of APOE ε4 and ε2 With Survival Without Neurological Disease

Fraction (%) of Carriers of the APOE ε4 or APOE ε2
Participant group Age ≤ 50 Age = 51–60 Age = 61–70 Age = 71–80 Age = 81–90 Age > 90 OR (95% CI) p Value
Association with APOE ε4
All participants (N = 1,483) 43/133 (32.3%) 41/168 (24.4%) 79/300 (26.3%) 78/294 (26.5%) 117/437 (26.8%) 46/145 (31.7%) 1.00 (0.93, 1.08) .92
Males (N = 649) 14/44 (31.8%) 12/65 (18.5%) 32/124 (25.8%) 35/134 (26.1%) 53/214 (24.8%) 21/64 (32.8%) 1.02 (0.90, 1.15) .78
Females (N = 834) 29/89 (32.6%) 29/103 (28.2%) 47/176 (26.7%) 43/160 (26.9%) 64/223 (28.7%) 25/81 (30.9%) 1.00 (0.91, 1.10) .93
Association with APOE ε2
All participants (N = 1,483) 19/133 (14.3%) 23/168 (13.7%) 42/300 (14.0%) 57/294 (19.4%) 83/437 (19.0%) 41/145 (28.5%) 1.17 (1.07, 1.29) .001
Males (N = 649) 5/44 (11.4%) 8/65 (12.3%) 19/124 (15.3%) 29/134 (21.6%) 36/214 (16.8%) 18/64 (28.1%) 1.14 (0.98, 1.32) .087
Females (N = 834) 14/89 (15.7%) 15/103 (14.6%) 23/176 (13.1%) 28/160 (17.5%) 47/223 (21.1%) 23/81 (28.9%) 1.20 (1.06, 1.35) .003

Notes: OR = odds ratio; CI = confidence interval. ORs, 95% CIs, and p-values result from binary logistic regression models (where the dependent variable was presence/absence of the ε4 allele, or presence/absence of the ε2 allele, and the independent variable was age at blood draw which was analyzed as a continuous variable) that were adjusted for sex in analysis of all patients, and were unadjusted in analysis of males and females. ORs are interpreted as the multiplicative increase in the odds of presence of the APOE ε4 allele (for analysis of APOE ε4) or presence of the APOE ε4 allele (for analysis of APOE ε4) corresponding to each 10-y increase in age at blood draw. The six different age categories were utilized for purposes of presentation only; age was analyzed as a continuous variable in all statistical tests of association. Information was unavailable regarding APOE genotype for six patients.